|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cancer and age related colonic crypt deficiencies in cytochrome c oxidase Ⅰ显示文摘AIM: To investigate whether defi ciency of expressionof cytochrome c oxidase I (CcOI) in colonic crypts is associated with colon cancer.METHODS: The pattern and level of expression of CcOI in non-neoplastic colonic crypts,and in dysplastic tissues,was assessed using standard immunohis-tochemical methods.Biopsies were obtained from individuals undergoing colonoscopies for screening purposes or for a medically indicated reason.Tissue samples were also obtained from surgical colonic resections.Samples from resections were taken from colonic mucosa 1 and 10 cm from tumors and from the tumors themselves.Samples were evaluated for frequency of crypts with reduced or absent expression of CcOI.In most crypts the loss was apparent throughout the entire crypt,while in a small minority the loss was segmental.The strong immunoreactivity using this monoclonal antibody makes the scoring unambiguous.The percent of crypts with reduced or absent expression of CcOI or (infrequent) segmented loss of expression was then calculated.Data analyses were performed using SPSS statistical package 17.0.RESULTS: The average frequency of CcOI deficient crypts (CcOI-DC) is low in individuals between 20 and 39 years of age,with 0.48% ± 0.40% CcOI-DC for women and 1.80% ± 0.35% for men.CcOI-DC increases after age 40 years,so that between the ages of 40 and 44 years the average frequency of CcOI- DC goes up to 5.89% ± 0.84% in women and 2.15% ± 1.27% in men.By 80-84 years of age,the average frequency of CcOI-DC goes up in women to 15.77% ± 0.97% and in men to 22.6% ± 0.65%.The increases in CcOI-DC from ages 40-44 years compared to 80-84 years in women and men are significantly different with P < 0.01.For women over age 60 years,deficiency of CcOI expression is greater in those women who have had a cancer in their colon.The frequency of CcOI-DC,measured in men,increased in tissues adjacent to colon cancer,being 4.03% ± 0.27% in individuals free of neoplasia in the age range 55-64 yearsand 14.13% ± 0.35% in resected histologically normal tissue of men with cancer in the same age range,P < 0.001.Similar signifi cant differences were noted in older age ranges.The frequency of CcOI-DC crypts in the cecum and sigmoid colon of an individual are signifi cantly correlated,with an R2 = 0.414 for women and R2 = 0.528 for men,P < 0.001.This suggests that the factors determining the level of CcOI deficiency act throughout the colon.Most defective crypts are in clusters of two or more,a likely consequence of crypt fission.In the non-neoplastic margins of cancers,crypts are frequently defi cient for CcOI,and such crypts may appear in large clusters,some containing more than 100 defi cient crypts.CcOI defi ciency is also apparent in colon cancers and sometimes involves a large section of the tumor.Overall,CcOI deficient cells can be visualized in segments of crypts,in whole crypts that increase in frequency with age,in crypts undergoing f ission,in clusters of crypts where the clusters increase in size with age,in increased frequency near tumors,in large clusters in the intimate margins of tumors,and in the tumors themselves.There is no clear dividing line between early stages that can be considered aspects of aging and later stages that can be considered aspects of the progression to cancer.This ambiguity may re ect a rather general situation leading to adult cancer where the early stages of cellular change appear to be relatively innocuous features of the aging process but over decades may evolve into malignancy.CONCLUSION: CcOI defi cient crypts increase in frequency with age,and clusters of defi cient crypts are associated with,and may give rise to,colon cancer. | Carol Bernstein Alexander Facista Huy Nguyen Beryl Zaitlin Nadia Hassounah Cristy Loustaunau Claire Margaret Payne Bhaskar Banerjee Steve Goldschmid V Liana Tsikitis Robert Krouse Harris Bernstein | 2010 | World Journal of Gastrointestinal Oncology2010，2，12： | 5 |
| 2 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 3 | Cholesteryl ester storage disease: Review of the findings in 135 reported patients with an underdiagnosed disease显示文摘 | Donna L. Bernstein Helena Hülkova Martin G. Bialer Robert J. Desnick | 2013 | Journal of Hepatology2013，，6： | 2 |
| 4 | WR-2721 (amifostine) infusion in patients with Ewing’s sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study显示文摘 | Abdul-Kader Souid Robert C. Fahey Ronald L. Dubowy Gerald L. Newton Mark L. Bernstein | 1999 | Cancer Chemotherapy and Pharmacology1999，，6： | 1 |
| 5 | Radiationeoxidation Mechanisms: Vola- tile Organic Degradation Products from Polypropylene Having Selective C-13 Labeling Studied by GC/MS显示文摘 | Robert Bernstein | 2008 | Polymer Degradation and Stability2008，，93： | 1 |
| 6 | Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers显示文摘 | Antoun Toubaji Moujahed Achtar Maurizio Provenzano Vincent E. Herrin Robert Behrens Michael Hamilton Sarah Bernstein David Venzon Barry Gause Francesco Marincola Samir N. Khleif | 2008 | Cancer Immunology Immunotherapy2008，，9： | 1 |
| 7 | The association between statin medication and progression after surgery for localized renal cell carcinoma显示文摘 | Robert J. Hamilton Daniel Morilla Fernando Cabrera Michael Leapman Ling Y. Chen Melanie Bernstein A Ari Hakimi Victor E. Reuter Paul Russo | 2013 | The Journal of Urology2013，，： | 1 |
| 8 | Colonoscopy and its complications across a Canadian regional health authority显示文摘 | Harminder Singh Robert B. Penfold Carolyn DeCoster Lisa Kaita Cindy Proulx Gerry Taylor Charles N. Bernstein Michael Moffatt | 2009 | Gastrointestinal Endoscopy2009，，3： | 1 |
| 9 | Evolution of Interstellar Ices显示文摘 | Louis J. Allamandola Max P. Bernstein Scott A. Sandford Robert L. Walker | | 0，1999，： | 1 |
| 10 | In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53显示文摘 | Yoshitaka Hosokawa Alexandros Papanikolaou Robert D. Cardiff Katsuhiko Yoshimoto Megan Bernstein Timothy C. Wang Emmett V. Schmidt Andrew Arnold | 2001 | Transgenic Research2001，，5： | 1 |
| 11 | Efficacy and Safety of Fexofenadine Hydrochloride for Treatment of Seasonal Allergic Rhinitis显示文摘 | David I Bernstein William F Schoenwetter Robert A Nathan William Storms Robert Ahlbrandt Jolene Mason | 1997 | Annals of Allergy Asthma & Immunology1997，，5： | 1 |
| 12 | Evidence of non - Arrhenius behaviour from laboratory aging and 24 - year field aging of polychloroprene rubber materials 显示文摘 | Kenneth T Gillen Robert Bernstein Dora K Derzon | 2005 | Polymer Degradation and Stability2005，87，1： | 1 |
| 13 | Con- dition monitoring approaches applied to the polychloroprene cable jacketing material显示文摘 | Kenneth T GilIen Roger A Assink Robert Bernstein | 2004 | Polymer Degredation and Sta- bility2004，84，： | 1 |
| 14 | Validation of improved methods for predicting long- term elastomerie seal lifetimes from compression stress- relaxation and oxygen consumption techniques 显示文摘 | KENNETH T GILLEN MATHEW CELINA ROBERT BERNSTEIN | 2003 | Polymer Degradation and Stability2003，82，： | 1 |
| 15 | Validation of improved methods for predicting long - term elastomeric seal lifetimes from compression stress -relaxation and oxygen consumption techniques显示文摘 | Kenneth T Gillen Mathew Celina Robert Bernstein | 2003 | Polymer Deg- radation and Stability2003，82，1： | 1 |
| 16 | Dose to the Contralateral Breast From Radiotherapy and Risk of Second Primary Breast Cancer in the WECARE Study显示文摘 | Marilyn Stovall Susan A. Smith Bryan M. Langholz John D. Boice Roy E. Shore Michael Andersson Thomas A. Buchholz Marinela Capanu Leslie Bernstein Charles F. Lynch Kathleen E. Malone Hoda Anton-Culver Robert W. Haile Barry S. Rosenstein Anne S. Reiner Dunc | 2008 | International Journal of Radiation Oncology, Biology, Physics2008，，4： | 1 |
| 17 | β-Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency——A Randomized,Placebo-Controlled,and Double-Blinded Trial显示文摘Objective:To test the hypothesis thatβ-glucan enhances protective qi(PQi),an important Chinese medicine(CM)concept which stipulates that a protective force circulates throughout the body surface and works as the first line of defense against'external pernicious influences'.Methods:A total of 138 participants with PQi deficiency(PQD)were randomized to receiveβ-glucan(200 mg daily)or placebo for 12 weeks.Participants’PQi status was assessed every 2 weeks via conventional diagnosis and a standardized protocol from which a PQD severity and risk score was derived.Indices of participants’immune and general health status were also monitored,including upper respiratory tract infection(URTI),saliva secretory Ig A(s Ig A),and self-reported measures of physical and mental health(PROMIS).Results:PQi status was not significantly different between theβ-glucan and placebo treatment groups at baseline but improved significantly in theβ-glucan(vs.placebo)group in a time-dependent manner.The intergroup differences[95%confidence interval(CI)]in severity score(scale:1-5),risk score(scale:0-1),and proportion of PQD participants(%)at finish line was 0.49(0.35-0.62),0.48(0.35-0.61),and 0.36(0.25-0.47),respectively.Additionally,β-glucan improved URTI symptom(scale:1-9)and PROMIS physical(scale:16.2-67.7)and mental(scale:21.2-67.6)scores by a magnitude(95%CI)of 1.0(0.21-1.86),5.7(2.33-9.07),and 3.0(-0.37-6.37),respectively,over placebo.Conclusions:β-Glucan ameliorates PQi in PQD individuals.By using stringent evidence-based methodologies,our study demonstrated that Western medicine-derived remedies,such asβ-glucan,can be employed to advance CM therapeutics.(Clinical Trial.Gov registry:NCT03782974) | WU Jun-rong CHENG Hao-jie SHI Jian-pin YIN Wei-dong WANG Jun OU Xuan-qiao CHEN Jin-li Ira Bernstein Mark Levy Rolando Maddela Robert Sinnott TIAN Jun-qiang | 2022 | Chinese Journal of Integrative Medicine2022，28，5： | 1 |
| 18 | A benchmark problem for nonlinear control design显示文摘 | Robert T B Bernstein D S Coppola V T | 1998 | International Journal of Robust and Nonlinear Control1998，8，45： | 1 |
| 19 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 1 |
| 20 | Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations显示文摘 | Harminder Singh Diane Bay Stephen Ip Charles N. Bernstein Zoann Nugent Rodica Gheorghe Robert Wightman | 2012 | Gastrointestinal Endoscopy2012，，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员